{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:04:54Z","timestamp":1792008294527,"version":"4.4.0"},"reference-count":184,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,26]],"date-time":"2020-01-26T00:00:00Z","timestamp":1579996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2015CB931800"],"award-info":[{"award-number":["2015CB931800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773620"],"award-info":[{"award-number":["81773620"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573332"],"award-info":[{"award-number":["81573332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.apsb.2020.01.015","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T11:59:42Z","timestamp":1580471982000},"page":"1347-1359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":169,"title":["Gene therapy for neurodegenerative disorders: advances, insights and prospects"],"prefix":"10.1016","volume":"10","author":[{"given":"Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2020.01.015_bib1","article-title":"Gene therapy comes of age","volume":"59","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.apsb.2020.01.015_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2020.01.015_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.01.015_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.preteyeres.2018.08.003","article-title":"Gene therapy for visual loss: opportunities and concerns","volume":"68","author":"Lee","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apsb.2020.01.015_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.03.004","article-title":"Adeno-associated virus (AAV) gene therapy for neurological disease","volume":"69","author":"Weinberg","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.apsb.2020.01.015_bib6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1089\/hum.2013.005","article-title":"Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the CSF of non-human primates","volume":"24","author":"Samaranch","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.apsb.2019.11.003","article-title":"Biomimetic carbon nanotubes for neurological disease therapeutics as inherent medication","volume":"10","author":"Xiang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.01.015_bib8","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/mt.2008.166","article-title":"Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain","volume":"16","author":"Cearley","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/hum.1998.9.8-1181","article-title":"Selective and rapid uptake of adeno-associated virus type 2 in brain","volume":"9","author":"Bartlett","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/gt.2011.71","article-title":"Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector","volume":"19","author":"Hutson","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac6191","article-title":"AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease","volume":"7","author":"Katz","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/gt.2011.130","article-title":"Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs","volume":"19","author":"Federici","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib13","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1128\/JVI.77.12.7034-7040.2003","article-title":"Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of \u03b2-glucuronidase deficient mice","volume":"77","author":"Passini","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2020.01.015_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1227\/NEU.0b013e318217217e","article-title":"T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery","volume":"69","author":"Richardson","year":"2011","journal-title":"Neurosurgery"},{"key":"10.1016\/j.apsb.2020.01.015_bib15","doi-asserted-by":"crossref","first-page":"16046","DOI":"10.1038\/mtm.2016.46","article-title":"Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs","volume":"3","author":"Miyanohara","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.apsb.2020.01.015_bib16","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2017.08.004","article-title":"AAV-PHP.B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy","volume":"25","author":"Morabito","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/hum.2014.011","article-title":"Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy","volume":"25","author":"Passini","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41596-018-0097-3","article-title":"Systemic AAV vectors for widespread and targeted gene delivery in rodents","volume":"14","author":"Challis","year":"2019","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2020.01.015_bib19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nbt.2618","article-title":"Broad protection against influenza infection by vectored immunoprophylaxis in mice","volume":"31","author":"Balazs","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2020.01.015_bib20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2020.01.015_bib21","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic l-amino acid decarboxylase deficiency","volume":"4","author":"Hwu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/humc.2017.010","article-title":"Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson's disease","volume":"28","author":"Sehara","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.apsb.2020.01.015_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib25","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/mt.2013.118","article-title":"Acat1 knockdown gene therapy decreases amyloid-beta in a mouse model of Alzheimer's disease","volume":"21","author":"Murphy","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12974-018-1139-z","article-title":"LncRNA H19 contributes to hippocampal glial cell activation via JAK\/STAT signaling in a rat model of temporal lobe epilepsy","volume":"15","author":"Han","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.apsb.2020.01.015_bib27","first-page":"2552","article-title":"In\u00a0vitro and in\u00a0vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery","volume":"25","author":"Garanto","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.apsb.2020.01.015_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib29","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib30","first-page":"S59","article-title":"Update on phase 1\/2 clinical trials for MPS I and MPS II using ZFN-mediated in\u00a0vivo genome editing","volume":"123","author":"Harmatz","year":"2018","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.apsb.2020.01.015_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41593-019-0352-0","article-title":"In\u00a0vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease","volume":"22","author":"Park","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.01.015_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2020.01.015_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models","volume":"13","author":"Spronck","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.apsb.2020.01.015_bib36","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib37","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.7150\/thno.18813","article-title":"MiR-196a enhances neuronal morphology through suppressing RANBP10 to provide neuroprotection in Huntington's disease","volume":"7","author":"Her","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2020.01.015_bib38","doi-asserted-by":"crossref","first-page":"930","DOI":"10.7150\/thno.7026","article-title":"MicroRNAs\u2014the next generation therapeutic targets in human diseases","volume":"3","author":"Srinivasan","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2020.01.015_bib39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","article-title":"Gene therapy for neurodegenerative diseases","volume":"16","author":"Sudhakar","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.apsb.2020.01.015_bib40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/mt.2010.248","article-title":"Anterograde axonal transport of AAV2-GDNF in rat basal ganglia","volume":"19","author":"Ciesielska","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib41","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1073\/pnas.0810682106","article-title":"Efficient gene therapy based method for the delivery of therapeutics to primate cortex","volume":"106","author":"Kells","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.01.015_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2016.24","article-title":"Axonal transport of AAV9 in nonhuman primate brain","volume":"23","author":"Green","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib44","doi-asserted-by":"crossref","first-page":"15238","DOI":"10.1128\/JVI.79.24.15238-15245.2005","article-title":"Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties","volume":"79","author":"Arbetman","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2020.01.015_bib45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ymthe.2005.09.009","article-title":"Identification of mouse AAV capsid-specific CD8+ T cell epitopes","volume":"12","author":"Sabatino","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib46","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2020.01.015_bib47","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1073\/pnas.0937739100","article-title":"Adeno-associated viruses undergo substantial evolution in primates during natural infections","volume":"100","author":"Gao","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.01.015_bib48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2020.01.015_bib49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2020.01.015_bib50","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.apsb.2020.01.015_bib51","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2020.01.015_bib52","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.gt.3302554","article-title":"Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS","volume":"12","author":"Liu","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib53","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.97.7.3428","article-title":"Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system","volume":"97","author":"Davidson","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.01.015_bib54","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/ncomms4075","article-title":"Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing","volume":"5","author":"Adachi","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.01.015_bib55","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ymthe.2017.10.017","article-title":"Mapping the structural determinants required for AAVrh.10 transport across the blood\u2013brain barrier","volume":"26","author":"Albright","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib56","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.neuron.2017.04.017","article-title":"Global representations of goal-directed behavior in distinct cell types of mouse neocortex","volume":"94","author":"Allen","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2020.01.015_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005708","article-title":"In\u00a0vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib58","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neurobiolaging.2018.02.008","article-title":"Age-related pathology after adenoviral overexpression of the leucine-rich repeat kinase 2 in the mouse striatum","volume":"66","author":"Kritzinger","year":"2018","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2020.01.015_bib59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0301-0082(98)00028-8","article-title":"Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases","volume":"55","author":"Barkats","year":"1998","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.apsb.2020.01.015_bib60","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2020.01.015_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrg2141","article-title":"Engineering targeted viral vectors for gene therapy","volume":"8","author":"Waehler","year":"2007","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2020.01.015_bib62","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2020.01.015_bib63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/hum.2006.17.253","article-title":"Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors","volume":"17","author":"Baum","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib64","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjp.2008.349","article-title":"Viral vectors: from virology to transgene expression","volume":"157","author":"Bouard","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2020.01.015_bib65","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","article-title":"Immune responses to gene therapy vectors: influence on vector function and effector mechanisms","volume":"11","author":"Bessis","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib66","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.01.015_bib67","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1775","article-title":"Design and development of polymers for gene delivery","volume":"4","author":"Pack","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.01.015_bib68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1021\/cr800409e","article-title":"Nonviral vectors for gene delivery","volume":"109","author":"Mintzer","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2020.01.015_bib69","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","article-title":"Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery","volume":"13","author":"Buck","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2020.01.015_bib70","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2020.01.015_bib71","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11095-006-9180-5","article-title":"Lipid-based nanoparticles for nucleic acid delivery","volume":"24","author":"Li","year":"2007","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2020.01.015_bib72","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biomaterials.2015.12.021","article-title":"Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype","volume":"82","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.01.015_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.biomaterials.2017.01.032","article-title":"The therapeutic contribution of nanomedicine to treat neurodegenerative diseases via neural stem cell differentiation","volume":"123","author":"Carradori","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.01.015_bib74","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7150\/thno.16562","article-title":"Inhibition by multifunctional magnetic nanoparticles loaded with \u03b1-synuclein RNAi plasmid in a Parkinson's disease model","volume":"7","author":"Niu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2020.01.015_bib75","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2020.01.015_bib76","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41467-018-03733-8","article-title":"Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment","volume":"9","author":"Kojima","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.01.015_bib77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.biomaterials.2018.09.046","article-title":"In\u00a0vivo hepatocellular expression of interleukin-22 using penetratin-based hybrid nanoparticles as potential anti-hepatitis therapeutics","volume":"187","author":"Chen","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.01.015_bib78","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.biomaterials.2012.10.013","article-title":"Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases","volume":"34","author":"Malhotra","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.01.015_bib79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.biomaterials.2015.04.052","article-title":"Arginine-rich polyplexes for gene delivery to neuronal cells","volume":"60","author":"Morris","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.01.015_bib80","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/mt.2013.285","article-title":"Recombinant AAV as a platform for translating the therapeutic potential of RNA interference","volume":"22","author":"Borel","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib81","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrd3050","article-title":"Protein aggregation diseases: pathogenicity and therapeutic perspectives","volume":"9","author":"Aguzzi","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.01.015_bib82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrn1007","article-title":"Unfolding the role of protein misfolding in neurodegenerative diseases","volume":"4","author":"Soto","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib83","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nature17041","article-title":"Protein misfolding in the endoplasmic reticulum as a conduit to human disease","volume":"529","author":"Wang","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.01.015_bib84","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1093\/emboj\/cdg537","article-title":"Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein","volume":"22","author":"Hetz","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2020.01.015_bib85","doi-asserted-by":"crossref","first-page":"9498","DOI":"10.1523\/JNEUROSCI.5397-12.2013","article-title":"Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation","volume":"33","author":"Abisambra","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib86","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1126\/science.1129462","article-title":"\u03b1-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models","volume":"313","author":"Cooper","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.apsb.2020.01.015_bib87","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.neuron.2011.11.026","article-title":"Differential effects of unfolded protein response pathways on axon injury-induced death of retinal ganglion cells","volume":"73","author":"Hu","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2020.01.015_bib88","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1523\/JNEUROSCI.3709-15.2016","article-title":"Rescue of glaucomatous neurodegeneration by differentially modulating neuronal endoplasmic reticulum stress molecules","volume":"36","author":"Yang","year":"2016","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.329","article-title":"Neuroprotection by eIF2\u03b1-CHOP inhibition and XBP-1 activation in EAE\/optic neuritiss","volume":"8","author":"Huang","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2020.01.015_bib90","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.brainres.2016.04.064","article-title":"Gene therapy to target ER stress in brain diseases","volume":"1648","author":"Valenzuela","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2020.01.015_bib91","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bbrc.2012.03.033","article-title":"AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease","volume":"420","author":"Zuleta","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2020.01.015_bib92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.brainres.2008.11.104","article-title":"Protective effect against Parkinson's disease-related insults through the activation of XBP1","volume":"1257","author":"Sado","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2020.01.015_bib93","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1073\/pnas.1321845111","article-title":"Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1","volume":"111","author":"Vald\u00e9s","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.01.015_bib94","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/mt.2012.28","article-title":"Glucose regulated protein 78 diminishes \u03b1-synuclein neurotoxicity in a rat model of Parkinson disease","volume":"20","author":"Gorbatyuk","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib95","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nn.3903","article-title":"Marinesco-Sj\u00f6gren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS","volume":"18","author":"Fil\u00e9zac de L'Etang","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aal2323","article-title":"Endoplasmic reticulum proteostasis in glioblastomas\u2014from molecular mechanisms to therapeutic perspectives","volume":"10","author":"Obacz","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.apsb.2020.01.015_bib97","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/carcin\/bgy041","article-title":"Disrupting CD47-SIRP\u03b1 axis alone or combined with autophagy depletion for the therapy of glioblastoma","volume":"39","author":"Zhang","year":"2018","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.apsb.2020.01.015_bib98","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.molmed.2011.07.008","article-title":"mTOR: a pathogenic signaling pathway in developmental brain malformations","volume":"17","author":"Crino","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib99","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1152\/physrev.00038.2014","article-title":"mTOR in brain physiology and pathologies","volume":"95","author":"Bockaert","year":"2015","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2020.01.015_bib100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The neurology of mTOR","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2020.01.015_bib101","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41419-018-1289-z","article-title":"AKT-dependent and -independent pathways mediate PTEN deletion-induced CNS axon regeneration","volume":"10","author":"Huang","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2020.01.015_bib102","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1126\/science.1161566","article-title":"Promoting axon regeneration in the adult CNS by modulation of the PTEN\/mTOR pathway","volume":"322","author":"Park","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.apsb.2020.01.015_bib103","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1038\/ncomms6416","article-title":"The mTORC1 effectors S6K1 and 4E-BP play different roles in CNS axon regeneration","volume":"5","author":"Yang","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.01.015_bib104","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.14908","article-title":"mTORC1 is necessary but mTORC2 and GSK3\u03b2 are inhibitory for AKT3-induced axon regeneration in the central nervous system","volume":"5","author":"Miao","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.apsb.2020.01.015_bib105","doi-asserted-by":"crossref","first-page":"18757","DOI":"10.1073\/pnas.0606401103","article-title":"Oncoprotein Akt\/PKB induces trophic effects in murine models of Parkinson's disease","volume":"103","author":"Ries","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.01.015_bib106","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1523\/JNEUROSCI.5519-10.2011","article-title":"Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy","volume":"31","author":"Cheng","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib107","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2741\/s310","article-title":"The role of mTOR signaling in Alzheimer's disease","volume":"4","author":"Oddo","year":"2012","journal-title":"Front Biosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib108","doi-asserted-by":"crossref","first-page":"27734","DOI":"10.1074\/jbc.M109.008177","article-title":"Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway","volume":"284","author":"Morita","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2020.01.015_bib109","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.neuron.2014.12.019","article-title":"Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes","volume":"85","author":"Lee","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2020.01.015_bib110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2020.01.015_bib111","doi-asserted-by":"crossref","first-page":"ra103","DOI":"10.1126\/scisignal.2005633","article-title":"Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease","volume":"7","author":"Pryor","year":"2014","journal-title":"Sci Signal"},{"key":"10.1016\/j.apsb.2020.01.015_bib112","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrd.2018.174","article-title":"Mitochondria as a therapeutic target for common pathologies","volume":"17","author":"Murphy","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.01.015_bib113","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/jpet.112.192138","article-title":"Mitochondrial dysfunction in neurodegenerative diseases","volume":"342","author":"Johri","year":"2012","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2020.01.015_bib114","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbadis.2009.10.007","article-title":"Mitochondria: a therapeutic target in neurodegeneration","volume":"1802","author":"Moreira","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2020.01.015_bib115","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.7150\/thno.20955","article-title":"Tethering interleukin-22 to apolipoprotein A-I ameliorates mice from acetaminophen-induced liver injury","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2020.01.015_bib116","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-pharmtox-010716-105001","article-title":"Mitochondrial mechanisms of neuronal cell death: potential therapeutics","volume":"57","author":"Dawson","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.apsb.2020.01.015_bib117","doi-asserted-by":"crossref","first-page":"15703","DOI":"10.1523\/JNEUROSCI.0552-11.2011","article-title":"The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease","volume":"31","author":"McManus","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib118","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice","volume":"355","author":"Williams","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.apsb.2020.01.015_bib119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12883-015-0272-x","article-title":"Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model","volume":"15","author":"Long","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1016\/j.apsb.2020.01.015_bib120","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nature13418","article-title":"The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy","volume":"510","author":"Bingol","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.01.015_bib121","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymthe.2004.09.007","article-title":"Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease","volume":"11","author":"Dong","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003799","article-title":"PGC-1\u03b1 rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function","volume":"4","author":"Tsunemi","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib123","doi-asserted-by":"crossref","first-page":"201","DOI":"10.14336\/AD.2015.1007","article-title":"Mitochondrial dysfunction in Alzheimer's disease and the rationale for bioenergetics based therapies","volume":"7","author":"Onyango","year":"2016","journal-title":"Aging Dis"},{"key":"10.1016\/j.apsb.2020.01.015_bib124","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2018.05.005","article-title":"Epigenetic regulation in neurodegenerative diseases","volume":"41","author":"Berson","year":"2018","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nature14252","article-title":"Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease","volume":"518","author":"Gjoneska","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.01.015_bib126","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41593-018-0101-9","article-title":"Dysregulation of the epigenetic landscape of normal aging in Alzheimer's disease","volume":"21","author":"Nativio","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib127","first-page":"878","article-title":"The yin and yang of \u03b1-synuclein-associated epigenetics in Parkinson's disease","volume":"140","author":"Pavlou","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2020.01.015_bib128","doi-asserted-by":"crossref","first-page":"E3027","DOI":"10.1073\/pnas.1311323110","article-title":"Targeting H3K4 trimethylation in Huntington disease","volume":"110","author":"Vashishtha","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.01.015_bib129","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/nn.3564","article-title":"EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia","volume":"16","author":"Li","year":"2013","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib130","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.01.015_bib131","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.01.015_bib132","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib133","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsmedchemlett.7b00414","article-title":"Dual NAMPT\/HDAC inhibitors as a new strategy for multitargeting antitumor drug discovery","volume":"9","author":"Chen","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.01.015_bib134","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1093\/brain\/awx272","article-title":"Epigenetic editing of the Dlg4\/PSD95 gene improves cognition in aged and Alzheimer's disease mice","volume":"140","author":"Bustos","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2020.01.015_bib135","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1093\/brain\/awz174","article-title":"CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease","volume":"142","author":"Kacher","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2020.01.015_bib136","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1474-4422(18)30238-2","article-title":"Selective autophagy as a potential therapeutic target for neurodegenerative disorders","volume":"17","author":"Scrivo","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2020.01.015_bib137","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.apsb.2019.10.003","article-title":"Targeting autophagy-related protein kinases for potential therapeutic purpose","volume":"10","author":"Xiang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.01.015_bib138","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1093\/brain\/awx258","article-title":"PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease","volume":"140","author":"Du","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2020.01.015_bib139","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1093\/brain\/awt131","article-title":"Boosting chaperone-mediated autophagy in\u00a0vivo mitigates \u03b1-synuclein-induced neurodegeneration","volume":"136","author":"Xilouri","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2020.01.015_bib140","doi-asserted-by":"crossref","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","article-title":"TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity","volume":"110","author":"Decressac","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.01.015_bib141","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuron.2015.06.026","article-title":"Endolysosomal deficits augment mitochondria pathology in spinal motor neurons of asymptomatic fALS mice","volume":"87","author":"Xie","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2020.01.015_bib142","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","article-title":"Microglia in neurodegeneration","volume":"21","author":"Hickman","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib143","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer's disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib144","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2020.01.015_bib145","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ajhg.2008.10.008","article-title":"Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE","volume":"83","author":"Bertram","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.apsb.2020.01.015_bib146","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41467-019-09118-9","article-title":"Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model","volume":"10","author":"Zhong","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.01.015_bib147","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3672","article-title":"Progranulin protects against amyloid \u03b2 deposition and toxicity in Alzheimer's disease mouse models","volume":"20","author":"Minami","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib148","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuron.2017.09.056","article-title":"Cell biology of astrocytesynapse interactions","volume":"96","author":"Allen","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2020.01.015_bib149","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.molmed.2019.04.010","article-title":"Astrocytes: emerging therapeutic targets in neurological disorders","volume":"25","author":"Valori","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/glia.23254","article-title":"Synthetic AAV\/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes","volume":"66","author":"Kunze","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.apsb.2020.01.015_bib151","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.expneurol.2010.10.016","article-title":"Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra","volume":"228","author":"Cannon","year":"2011","journal-title":"Exp Neurol"},{"key":"10.1016\/j.apsb.2020.01.015_bib152","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s13346-017-0368-5","article-title":"Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood\u2013brain barrier as a strategy for inhibiting HIV replication in astrocytes","volume":"7","author":"Gu","year":"2017","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.apsb.2020.01.015_bib153","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1021\/acs.molpharmaceut.7b01084","article-title":"In\u00a0vivo introduction of mRNA encapsulated in lipid nanoparticles to brain neuronal cells and astrocytes via intracerebroventricular administration","volume":"15","author":"Tanaka","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2020.01.015_bib154","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1038\/s41467-019-11190-0","article-title":"Highly branched poly(\u03b2-amino ester) delivery of minicircle DNA for transfection of neurodegenerative disease related cells","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.01.015_bib155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.biomaterials.2015.12.008","article-title":"Nano and microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: application to Huntington's disease","volume":"83","author":"Andr\u00e9","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.01.015_bib156","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1038\/s41467-019-11150-8","article-title":"Activation of neuronal genes via LINE-1 elements upon global DNA demethylation in human neural progenitors","volume":"10","author":"J\u00f6nsson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.01.015_bib157","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2020.01.015_bib158","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2020.01.015_bib159","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/humc.2013.208","article-title":"Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates","volume":"25","author":"Murrey","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.apsb.2020.01.015_bib160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gt.2011.216","article-title":"Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems","volume":"20","author":"Mattar","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib161","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/mt.2016.84","article-title":"In\u00a0vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy","volume":"24","author":"Choudhury","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib162","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/mt.2015.231","article-title":"Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector","volume":"24","author":"Choudhury","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib163","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2020.01.015_bib164","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","article-title":"A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease","volume":"27","author":"Cearley","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/hum.2017.026","article-title":"Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib166","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib167","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib168","doi-asserted-by":"crossref","first-page":"11923","DOI":"10.1523\/JNEUROSCI.2795-06.2006","article-title":"Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid \u03b2, amyloid \u03b240, and amyloid \u03b242 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice","volume":"26","author":"Levites","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2020.01.015_bib169","doi-asserted-by":"crossref","first-page":"16060","DOI":"10.1038\/mtm.2016.60","article-title":"Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy","volume":"3","author":"Armbruster","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.apsb.2020.01.015_bib170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/acn3.162","article-title":"SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice","volume":"2","author":"Dirren","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.apsb.2020.01.015_bib171","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jconrel.2017.12.029","article-title":"High-efficiency transduction of spinal cord motor neurons by intrauterine delivery of integration-deficient lentiviral vectors","volume":"273","author":"Ahmed","year":"2018","journal-title":"J Contr Release"},{"key":"10.1016\/j.apsb.2020.01.015_bib172","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2020.01.015_bib173","article-title":"Single stranded adeno-associated virus achieves efficient gene transfer to anterior segment in the mouse eye","volume":"12","author":"Wang","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.apsb.2020.01.015_bib174","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/gt.2011.151","article-title":"Novel adeno-associated viral vectors for retinal gene therapy","volume":"19","author":"Vandenberghe","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib175","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.molmed.2018.06.006","article-title":"Seeing the light after 25 years of retinal gene therapy","volume":"24","author":"Trapani","year":"2018","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib176","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ymthe.2018.08.003","article-title":"Breaking and sealing barriers in retinal gene therapy","volume":"26","author":"Miller","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib177","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ymthe.2016.10.008","article-title":"Improved intravitreal AAV-mediated inner retinal gene transduction after surgical internal limiting membrane peeling in cynomolgus monkeys","volume":"25","author":"Takahashi","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib178","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","article-title":"A newAAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model","volume":"25","author":"Biferi","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib179","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000659","article-title":"Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness","volume":"2","author":"Amado","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.01.015_bib181","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the complex story of immune responses to AAV vectors trial after trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib182","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant adenoassociated viral integration and genotoxicity: insights from animal models","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.01.015_bib183","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2020.01.015_bib184","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138351931007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138351931007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:43:08Z","timestamp":1761928988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221138351931007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":184,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S221138351931007X"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2020.01.015","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for neurodegenerative disorders: advances, insights and prospects","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2020.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}